Nordic Nanovector and PSI team up to develop new ARCs for treating leukaemias

Posted: 11 April 2016 | Victoria White, Digital Content Producer | No comments yet

The collaboration aims to develop new antibody radionuclide conjugates (ARCs) optimised for the treatment of single cell leukaemias…

Nordic Nanovector has entered into a research and development collaboration programme with Paul Scherrer Institute (PSI) with the aim of developing new antibody radionuclide conjugates (ARCs) optimised for the treatment of single cell leukaemias, such as chronic lymphocytic leukaemia (CLL) and acute myeloid leukaemia (AML). 

The collaboration will explore the use of different radionuclide payloads, provided by PSI, linked to Nordic Nanovector’s chimeric anti-CD37 antibody (NNV003) to combine specific tumour-targeting with tumour-eradicating radiation. Successful candidates are expected to be advanced into preclinical and clinical trials.

The collaboration will benefit from grant funding recently awarded to Nordic Nanovector from the Research Council of Norway’s user-driven research-based innovation program (in Norwegian; Brukerstyrt innovasjonsarena, BIA).

Nordic Nanovector to benefit from PSI’s world-class radionuclide research

Commenting on the collaboration, Nordic Nanovector’s Chief Scientific Officer, Jostein Dahle, said: “We are delighted that, through this new collaboration, we can benefit from the world-class radionuclide research emanating from PSI to further enhance our own expertise in ARCs. We believe that the potential of our CD37-targeting approaches provides an excellent framework for us to create a pipeline of ARCs with profiles suitable for treating multiple types of leukaemia and lymphoma. This project is a positive step towards Nordic Nanovector’s mission of extending and improving the lives of patients with haematological cancers.”

Nordic Nanovector’s most advanced ARC, Betalutin, which comprises the murine anti-CD37 antibody (HH1) conjugated to lutetium-177, is currently in a Phase 1/2 clinical trial for the treatment of third and second line non-Hodgkin lymphoma (NHL).  Betalutin has the potential to be a very valuable treatment alternative for NHL, another very serious and highly prevalent haematological disease, based on the promising efficacy, safety and sustained duration of response data that has been observed in clinical studies to-date.

Related conditions